A year in Oncology

A Review of 2020 Drug Approvals & Key Milestones

Despite a global pandemic, 2020 saw a notable number of approvals of new anti-cancer therapies in the US, Europe and Japan – including the continued roll-out of immuno-oncology (I-O) therapies.

The US saw a similar number of new oncology drug/indication approvals in 2020 as in 2019. An even higher number were seen in Japan, largely due to approvals ahead of all other global regions (as per the Sakigake Designation Scheme) and the rollout of drugs already sanctioned by the FDA. In Europe, however, there were around a quarter fewer approvals in 2020 than in the prior year.

To view the approvals and the key milestones (in our view) in an easy-to-digest snapshot, please see Ipsos’ infographic, ‘A Year in Oncology: A Review of 2020 Drug Approvals in US, Europe & Japan’.

 

Related news

  • KEYS: Screen time

    [WEBINAR] KEYS: Screen time

    At our first KEYS webinar of the year we’ll be looking at what’s really happening on screens these days. What’s changing? What’s enduring? And how can businesses do better when it comes to engaging with people on their screens, in real time?
  • [Webinar] KEYS: What can we learn from what happened in 2025?
    Brand Image Webinar

    [Webinar] KEYS: What can we learn from what happened in 2025?

    In this final KEYS webinar of the year, we’ll be looking at the last 12 months through the rear-view mirror.
  • [Webinar] KEYS: THE MIDDLE CLASS: In Crisis?
    Society Webinar

    [Webinar] KEYS: THE MIDDLE CLASS: In Crisis?

    At our next KEYS webinar, we’ll be sharing on-the-ground perspectives as people give us their in-the-moment takes on how they see their lives - and their status in life - these days. Along the way we’ll hear about freedom (in the US), familismo (in Mexico) and understatedness (in the UK).